Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Precigen
Historische aandelenkoersen
Huidige aandelenkoers	US$5.52
52 Week Hoogtepunt	US$5.68
52 Week Laag	US$1.39
Bèta	1.06
1 maand verandering	30.19%
3 maanden verandering	50.41%
1 Jaar Verandering	286.01%
3 jaar verandering	425.71%
5 jaar verandering	-15.73%
Verandering sinds IPO	-77.68%

Recent nieuws en updates

Analyseartikel • Jun 21

Precigen (PGEN) Stock Could Be 79% Undervalued After FDA Exclusivity Win

Precigen (PGEN) is back in focus after the FDA granted orphan drug exclusivity to PAPZIMEOS for adult recurrent respiratory papillomatosis, limiting similar competing therapies for seven years and defining a clearer commercial runway. See our latest analysis for Precigen. The FDA decision comes after a period of strong momentum for Precigen, with the share price delivering a 46.95% 3 month share price return and a very large 1 year total shareholder return. However, the 5 year total...

Recent updates

Analyseartikel • Jun 21

Precigen (PGEN) Stock Could Be 79% Undervalued After FDA Exclusivity Win

Seeking Alpha • May 21

Precigen: Why I Am More Cautious After The Q1 Beat (Downgrade)

Summary Precigen, Inc. delivered $21.6M in Q1 Papzimeos revenue, aligning with bullish expectations but leaving key launch metrics undisclosed. Management projects cash flow breakeven by year-end, but tight cash, high burn, and future margin compression raise execution risk. Papzimeos momentum is positive, yet a lack of patient-level data and potential for pent-up demand clouds true organic growth visibility. Downgrade PGEN to Hold: risk-reward has contracted, and downside risk looms if Papzimeos underdelivers relative to already-baked-in expectations. Read the full article on Seeking Alpha

Seeking Alpha • Feb 28

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement

Summary BLA of PRGN-2012 for patients with Recurrent Respiratory Papillomatosis was accepted by FDA with a Priority Review date of August 27th of 2025. Marketing approval of PRGN-2012 for RRP would be huge because there is no FDA approved drugs for RRP. Also, there are an estimated 27,000 people in the United States who have it. PGEN is looking to form a strategic partnership or collaboration agreement to advance its UltraCAR-Ts. This technology is crucial because it could change CAR-T landscape for the better. PRGN-3006 is an UltraCAR-T being developed to target patients with Acute Myeloid Leukemia; PRGN-3008 is an UltraCAR-T targeting patients with CD19 solid tumors and autoimmune disorders. Read the full article on Seeking Alpha

Seeking Alpha • Feb 10

Precigen: Successful Proof Of Platform, But Cash Worries Remain

Summary Precigen's lead asset, PRGN-2012, shows promising results in treating Recurrent Respiratory Papillomatosis, achieving a 51% complete response rate and reducing surgical interventions. Financially, Precigen has a market cap of $468mn and a cash runway into 2026, but needs more funds for commercialization. The company is prioritizing PRGN-2012's development, restructuring operations, and cutting 20% of its workforce to extend its cash runway. Despite financial risks, Precigen's proven platforms and promising data make it a potential worthwhile investment, pending resolution of cash issues. Read the full article on Seeking Alpha

Analyseartikel • Feb 28

We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Jan 20

Precigen: RRP Targeting With AdenoVerse Technology Platform

Summary FDA agreed to allow phase 1/2 study to serve as the basis for being able to file for Accelerated Approval of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. A BLA filing of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis is expected in the 2nd half of 2024. It is projected that it could earn $2 billion in peak sales globally of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. PRGN-2009 which also uses the AdenoVerse technology has one phase 2 study targeting OPSCC underway and another one targeting recurrent/metastatic cervical cancer patients expected to begin in 2024. Read the full article on Seeking Alpha

Analyseartikel • Nov 04

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analyseartikel • Jul 18

Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Rendement voor aandeelhouders

	PGEN	US Biotechs	US Markt
7D	14.5%	5.1%	-2.7%
1Y	286.0%	36.7%	18.6%

Rendement versus industrie: PGEN overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 36.7 % opleverde.

Rendement versus markt: PGEN overtrof de US markt, die het afgelopen jaar een rendement opleverde van 18.6 %.

Prijsvolatiliteit

Is PGEN's price volatile compared to industry and market?
PGEN volatility
PGEN Average Weekly Movement	13.4%
Biotechs Industry Average Movement	10.6%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van PGEN is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 13% ) van PGEN is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1998	160	Helen Sabzevari	precigen.com

Precigen, Inc, een biofarmaceutisch bedrijf in een ontdekkings- en klinische fase, ontwikkelt gen- en celtherapieën die gebruikmaken van precisietechnologie om ziekten aan te pakken op het gebied van immuno-oncologie, auto-immuunziekten en infectieziekten. Het bedrijf biedt therapeutische platforms bestaande uit het AdenoVerse-platform, dat gebruikmaakt van een bibliotheek van gepatenteerde adenovectors voor gentoediening van therapeutische effectoren, immunomodulatoren en vaccinantigenen; en UltraCAR-T om chimere antigen receptor T-celtherapieën te bieden aan kankerpatiënten. Het ontwikkelt ook programma's gebaseerd op het UltraCAR-T platform, waaronder PRGN-3005 in Fase 1/1b klinische studie voor de behandeling van gevorderde eierstok-, eileider- of primaire peritoneale kanker; PRGN-3006 in Fase 1b studie voor patiënten met recidief of refractaire acute myeloïde leukemie en hoog-risico myelodysplastische syndromen; en PRGN-3007 in Fase 1/1b studie voor de behandeling van gevorderde receptor tyrosine kinase-achtige orphan receptor 1-positieve, hematologische en solide tumoren.

Precigen, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Precigen zich tot de beurswaarde?
PGEN fundamentele statistieken
Marktkapitalisatie	US$1.93b
Inkomsten(TTM)	-US$383.42m
Inkomsten(TTM)	US$31.60m

62.3x

P/S-verhouding

-5.1x

Koers/Winstverhouding

Is PGEN overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
PGEN resultatenrekening (TTM)
Inkomsten	US$31.60m
Kosten van inkomsten	US$42.78m
Brutowinst	-US$11.18m
Overige uitgaven	US$372.24m
Inkomsten	-US$383.42m

Laatst gerapporteerde inkomsten

Mar 31, 2026

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.08
Brutomarge	-35.39%
Nettowinstmarge	-1,213.54%
Schuld/Eigen Vermogen Verhouding	462.2%

Hoe presteerde PGEN op de lange termijn?

Bekijk historische prestaties en vergelijking

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/06/25 05:19
Aandelenkoers aan het einde van de dag	2026/06/25 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Precigen, Inc. wordt gevolgd door 10 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Ying Huang	Barclays
Derik de Bruin	BofA Global Research
Justin Walsh	B. Riley Securities, Inc.

Precigen (PGEN) Aandelenoverzicht

Beloningen

Risicoanalyse

Analyst Price Targets

Gene And Immunotherapy Expansion Will Drive Durable Long Term Opportunity

Top Analyst Narratives

Gene And Immunotherapy Expansion Will Drive Durable Long Term Opportunity

Precigen, Inc. Concurrenten

COMPASS Pathways

Tyra Biosciences

Sionna Therapeutics

Palvella Therapeutics

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Precigen Gains Seven-Year FDA Exclusivity for PAPZIMEOS in Rare Respiratory Disease

Precigen (PGEN) Stock Could Be 79% Undervalued After FDA Exclusivity Win

Precigen CFO Sells Shares as PAPZIMEOS Gains FDA Approval and Orphan Drug Exclusivity

President recently sold US$520k worth of stock

Precigen Presents New Long-Term Durability Data for Papzimeos and Receives Seven-Year Market Exclusivity

Precigen Reports Multi-Year PAPZIMEOS Durability With FDA Exclusivity in Rare Disease Market

Recent updates

Precigen Gains Seven-Year FDA Exclusivity for PAPZIMEOS in Rare Respiratory Disease

Precigen (PGEN) Stock Could Be 79% Undervalued After FDA Exclusivity Win

Precigen CFO Sells Shares as PAPZIMEOS Gains FDA Approval and Orphan Drug Exclusivity

President recently sold US$520k worth of stock

Precigen Presents New Long-Term Durability Data for Papzimeos and Receives Seven-Year Market Exclusivity

Precigen Reports Multi-Year PAPZIMEOS Durability With FDA Exclusivity in Rare Disease Market

Precigen: Why I Am More Cautious After The Q1 Beat (Downgrade)

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

Precigen, Inc. to Report Q1, 2026 Results on May 13, 2026

Precigen, Inc., Annual General Meeting, Jun 18, 2026

Executive Chairman recently sold US$7.7m worth of stock

Consensus revenue estimates increase by 17%

New minor risk - Share price stability

Full year 2025 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Fiscal Year 2025 Results on Mar 25, 2026

Precigen, Inc. Announces the Publication for The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis

Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-And-Only Fda-Approved Therapy for RRP

Executive Chairman notifies of intention to sell stock

Independent Director recently sold US$856k worth of stock

Independent Director recently sold US$856k worth of stock

Independent Director notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Consensus EPS estimates fall by 124%, revenue upgraded

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Shareholder dilution

Precigen, Inc. to Report Q3, 2025 Results on Nov 13, 2025

Precigen, Inc. Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses After Treatment with Papzimeos

Executive Chairman recently sold US$6.2m worth of stock

New minor risk - Insider selling

Independent Director notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Precigen, Inc. announced that it expects to receive $125 million in funding

Consensus EPS estimates fall by 13%, revenue upgraded

Price target increased by 18% to US$7.25

Precigen, Inc. Announces Full FDA Approval of PAPZIMEOS (Zopapogene Imadenovec-Drba)

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 24%, EPS downgraded

President exercised options and sold US$756k worth of stock

Forecast breakeven date pushed back to 2027

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Precigen, Inc., Annual General Meeting, Jun 26, 2025

Consensus revenue estimates fall by 25%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Fiscal Year 2024 Results on Mar 19, 2025

Consensus revenue estimates increase by 42%

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement

Precigen, Inc. Announces FDA Grants Priority Review to its BLA for PRGN-2012 for Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Precigen: Successful Proof Of Platform, But Cash Worries Remain

Precigen, Inc. announced that it has received $79 million in funding

New minor risk - Share price stability

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Precigen, Inc. announced that it expects to receive $79 million in funding

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Precigen Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Rule

Consensus revenue estimates fall by 12%

Price target decreased by 41% to US$6.00

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q2, 2024 Results on Aug 14, 2024

New minor risk - Shareholder dilution